Related Experiment Video
Updated: Jun 10, 2025

A Simple Pit Assay Protocol to Visualize and Quantify Osteoclastic Resorption In Vitro
Published on: June 16, 2022
Stage-specific modulation of multinucleation, fusion, and resorption by the long non-coding RNA DLEU1 and miR-16 in
Sara Reis Moura1,2,3, Ana Beatriz Sousa1,2,3, Jacob Bastholm Olesen4,5,6
1i3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
Abstract:
Osteoclasts are the only cells able to resorb all the constituents of the bone matrix. While the modulation of osteoclast activity is well established for preventing bone-related diseases, there is an increasing demand for novel classes of anti-resorption agents. Herein, we investigated non-coding RNA molecules and proposed DLEU1 and miR-16 as potential candidates for modulating osteoclast functions. DLEU1 and miR-16 target cell fusion at both the early and late stages of osteoclastogenesis but operate through independent pathways. DLEU1 silencing hinders the fusion process, leading to abrogation of the phagocytic cup fusion modality and a reduction in the fusion events between mononucleated precursors and multinucleated osteoclasts, while miR-16 influences monocyte-to-osteoclast differentiation, impairing osteoclasts formation but not the number of nuclei at early stages. On the other hand, using these non-coding RNAs to engineer mature osteoclasts has implications for bone resorption. Both DLEU1 and miR-16 influence the speed of resorption in pit-forming osteoclasts, without affecting the resorbed area. However, the impact of increasing miR-16 levels extends more broadly, affecting trench-forming osteoclasts as well, leading to a reduction in their percentage, speed, and resorbed area. These findings offer potential new therapeutic targets to ameliorate bone destruction in skeletal diseases.
Insights
Novel non-coding RNAs, DLEU1 and miR-16, show potential for treating bone diseases by modulating osteoclast activity and bone resorption. These molecules offer new therapeutic targets for skeletal conditions.
Area of Science:
- Cell Biology
- Molecular Biology
- Biochemistry
Background:
- Osteoclasts are crucial for bone resorption, and their modulation is key in preventing bone diseases.
- There is a need for new anti-resorption agents beyond current therapies.
Purpose of the Study:
- To investigate non-coding RNAs (ncRNAs) DLEU1 and miR-16 as novel therapeutic targets for modulating osteoclast function.
- To elucidate the distinct mechanisms by which DLEU1 and miR-16 affect osteoclastogenesis and bone resorption.
Main Methods:
- Investigated the role of DLEU1 and miR-16 in osteoclast differentiation and fusion using cell culture models.
- Analyzed the impact of DLEU1 and miR-16 on osteoclast formation, nuclearity, and bone resorption.
- Utilized techniques to assess cell fusion, monocyte differentiation, and resorption pit formation.
Main Results:
- DLEU1 silencing impaired osteoclast fusion by affecting the phagocytic cup modality and reducing fusion events.
- miR-16 influenced monocyte differentiation, impacting osteoclast formation but not nuclear number at early stages.
- Both ncRNAs affected resorption speed in pit-forming osteoclasts; increased miR-16 also reduced trench formation and resorbed area.
Conclusions:
- DLEU1 and miR-16 represent promising ncRNA targets for developing novel therapies against bone-related diseases.
- These ncRNAs offer distinct pathways to control osteoclastogenesis and bone resorption, providing versatile therapeutic strategies.
- Targeting DLEU1 and miR-16 could ameliorate bone destruction in various skeletal pathologies.
Related Concept Videos
Osteoclasts in Bone Remodeling
lncRNA - Long Non-coding RNAs
Bone Remodeling
MicroRNAs
The Nucleolus

